Estimated study duration Clause Samples
Estimated study duration. The study is planned to last from Q1 2008 to ▇▇ ▇▇▇▇. The clinical study phase is 180 days for each patient. A long term safety follow-up will include visits at Months 12, 24, 36, 48, and 60. Patients will be consented for the entire 5 year period.
Estimated study duration. It is estimated that the study duration for participants in the active treatment phase will be 6 months consisting of 14 days for screening, 2 months of treatment (at Day 1, 29 and 57) depending on tolerability to aflibercept ± OPT-302 (or sham) and week 12 and 24 follow-up visits. For the study participants who enter the run-in phase, there will be an additional ~4 to 6 weeks prior to entry into the active treatment phase.